A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
Love Goyal(The Christie NHS Foundation Trust), D.C. Bensen(Electronic BioSciences (United States)), Rachna T. Shroff(University of Arizona), C.T. Chen(Palo Alto University), Isaac Hoffman(Electronic BioSciences (United States)), Mitesh J. Borad(Jacksonville College), Tim Harris(Electronic BioSciences (United States)), James M. Cleary(Brigham and Women's Hospital), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Kari Nelson(Electronic BioSciences (United States)), Daniel DiToro(Brigham and Women's Hospital), Hiroshi Hirai(Taiho Pharmaceutical (Japan)), Nataliya V. Uboha(Wisconsin Division of Public Health), Keith T. Flaherty(Cancer Research Center), Thomas B. Karasic(Hospital of the University of Pennsylvania), Laxmi Parida(IBM (United States)), Hiroshi Sootome(Taiho Pharmaceutical (Japan)), Jochen Maurer(Universitätsklinikum Aachen), James R. Stone(Harvard University), Umair Majeed(Mayo Clinic in Florida), Jean Fan(Johns Hopkins University), C. Pinto(Harvard University), Brian P. Danysh(Broad Institute), P. Peng, Avinash Kambadakone(Harvard University), Islam Baiev(Massachusetts General Hospital), John D. Gordan(University of California, San Francisco), Caixia Sun(Sinopec (China)), Bo Lin(Virginia Mason Medical Center), Frank Wu, J.E. Berchuck(Brigham and Women's Hospital), Ignaty Leshchiner(Broad Institute), Kabir Mody(Mayo Clinic in Florida), M. M. Javle(The University of Texas MD Anderson Cancer Center), D. Vasseur(Inserm), N. Damjanov(University of Pennsylvania), Sylvia A. Reyes(Duke University), Charlotte S. Walmsley(Harvard University), S. Iyer(Electronic BioSciences (United States)), Ramakrishnan Iyer(Roswell Park Comprehensive Cancer Center), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Karen Zhang(UCSF Helen Diller Family Comprehensive Cancer Center), Liang Li(Chengdu University), Sudipta Saha(Fred Hutch Cancer Center), E Martin(Broad Institute), William Proctor Harris(University of Washington), E. Wehrenberg-Klee(Harvard University), H. Wang, Francesco Facchinetti(Inserm)
Cited by 33
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k